{"schema_version":"secwatch.filing_event.v1","accession":"0001516551-25-000002","form_type":"8-K","ticker":"SKYE","cik":"0001516551","company_name":"Skye Bioscience, Inc.","filed_at":"2025-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.857329+00:00","generated_at":"2026-05-26T03:31:03.618071+00:00","sec_items":["5.02","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Skye Bioscience board approves amended inducement equity plan with broader change-in-control authority","bullets":["Amendment gives administrator broader authority to cancel, assume, accelerate, or cash out outstanding awards upon a Change in Control.","Total shares authorized under the plan remain 600,000; no change to share pool.","Plan is used for inducement grants to new employees; all awards must be approved by a majority of independent directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001516551-25-000002","json":"https://secwatch.observer/filing/0001516551-25-000002.json","markdown":"https://secwatch.observer/filing/0001516551-25-000002.md","text":"https://secwatch.observer/filing/0001516551-25-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1516551/000151655125000002/0001516551-25-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1516551/000151655125000002/skye-20250224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T03:31:03.618071+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}